AJAdrien Joseph

Adrien Joseph

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adrien Joseph has a total of 380 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immune Profile and Risk of COVID-19-Associated Pulmonary Aspergillosis (CAPA): A Multicenter Retrospective Study with Matching Cohorts

    by Olivier Mascle, Claire Dupuis, Antoine Lafarge, Maxime Moniot, Bertrand Evrard, Philippe Poirier, Adrien Joseph, Elie Azoulay, Guillaume Dumas, Thibault Dupont, et al.

    Background: The anti-inflammatory effects of COVID-19 and its treatment may promote COVID-19-associated pulmonary aspergillosis (CAPA). This study aimed to investigate the immunological profile associated with CAPA in ICU patients. Methods: We conducted a retrospective study in three French ICUs. Severe COVID-19 patients who underwent immunological profiling within 10 days of ICU admission were included. CAPA patients were matched with non-CAPA patients to assess risk factors. Results: Among 479 non-CAPA patients, 52 were matched with 28 CAPA patients. CAPA patients more frequently required organ support (p < 0.01), but mortality rates were similar. At ICU admission and day 7, CAPA patients had higher serum IL-6, IL-10, and IL-6/mHLA-DR ratios. In univariate conditional logistic regression an mHLA-DR expression > 8000 antibodies/cell at admission was associated with lower CAPA (OR = 0.41 [0.17–0.99], p = 0.04) and CAPA or death (OR = 0.26 [0.08–0.81], p = 0.04). An IL-6/mHLA-DR ratio > 2.8 tended to be associated with CAPA or death (OR = 3.16 [0.98–10.21], p = 0.05). Multivariate analysis did not find an association between immunological data and development of CAPA. Conclusions: We did not find an association between early immunological profiling data and development of CAPA in multivariate analysis. However, mHLA-DR, IL-10 and IL-6/mHLA-DR ratios may be interesting directions for future research with larger cohorts.

  • Defining right ventricular injury in septic shock: insights from prospective echocardiographic cohorts

    by Adrien Joseph, Bruno Evrard, Cyril Charron, Gwenaël Prat, Alexis Dürr, Michel Slama, Philippe Vignon, Antoine Vieillard-Baron


  • Open Access

    Cell death–induced release of the pro-aging protein acyl CoA binding protein (ACBP) into the circulation

    by Yan Rong, Flavia Lambertucci, Yaning Yang, Vincent Carbonnier, Hui Chen, Yanbing Dong, Silvia Mingoia, Sijing Li, Omar Motiño, Léa Montégut, et al.

    Acyl-CoA–binding protein (ACBP, encoded by diazepam binding inhibitor, DBI) is an abundant intracellular regulator of lipid metabolism that also circulates systemically, yet the mechanisms governing its release and its relationship to organ injury remain unresolved. Herein, we combine human multi-omics, mechanistic mouse models and controlled cell death assays to identify cell death–driven liberation of intracellular ACBP/DBI as a unifying mechanism underlying its elevation in disease. In a cohort of 1198 hospitalized adults, among whom 75% were acutely infected by SARS-CoV-2, plasma ACBP/DBI tightly correlated with inflammatory markers and biochemical signatures of cardiac, hepatic, renal, metabolic and hematologic dysfunction. SomaScan proteomics further revealed that ACBP/DBI co-varies with organ-enriched proteins, particularly those originating from skeletal muscle and pancreas, implicating tissue injury as a major determinant of its circulating abundance. Multiple forms of acute organ damage in mice, including hepatic or renal ischemia-reperfusion, bile duct ligation, pancreatitis and rhabdomyolysis, triggered rapid and robust increases in plasma ACBP/DBI. Using defined in vitro paradigms, we demonstrate that apoptosis, ferroptosis and necroptosis each cause loss of intracellular ACBP/DBI and its release upon plasma membrane permeabilization, independent of the upstream lethal pathway. These mechanistic insights translated in vivo: hepatocyte apoptosis, ferroptosis and necroptosis each elevated circulating ACBP/DBI in a manner attenuated by pathway-specific inhibitors. Finally, meta-analysis of >100,000 individuals across diverse populations revealed that elevated plasma ACBP/DBI consistently associates with systemic and organ-specific disease and predicts future morbidity. Together, our findings identify cell death–driven ACBP/DBI release as a conserved mechanism linking organ injury to increased plasma ACBP/DBI, positioning this molecule as an integrative biomarker of tissue damage across species, organs, and cell death modalities.


  • Metabolic Roles of Acyl Coenzyme A-Binding Protein (ACBP)/Diazepam Binding Inhibitor (DBI)

    by Adrien Joseph

    Rôles métaboliques d’acyl coenzyme A-binding protein (ACBP)/diazepam binding inhibitor (DBI): L’obésité est un important problème de santé publique et a pris des proportions épidémiques chez les adultes et les enfants au cours des dernières décennies. Acyl coenzyme A binding protein (ACBP), également connue sous le nom de diazepam binding inhibitor (DBI), est une protéine aux fonctions multiples possédant des actions intracellulaires au travers du transport de molécules d’acyl-CoA et de la régulation du métabolisme lipidique (en tant qu’ACBP) et extracellulaires au travers de son interaction avec le site de fixation aux benzodiazépines du récepteur de l’acide γ-aminobutyrique (GABA) (en tant que DBI). Récemment, il a été montré que sa neutralisation génétique ou à l’aide d’anticorps entraine des effets anorexigènes, réduisant la prise alimentaire et la prise de poids et induisant des réactions lipo-cataboliques chez la souris. Cependant du fait de son action centrale, la crainte d’effets indésirables neurologiques ou psychiatriques limite son potentiel en tant que traitement de l’obésité chez l’Homme. Au cours de mon projet de thèse, nous nous sommes d’abord intéressés aux rôles psychiatriques d’ACBP/DBI. Nous avons montré que l’injection intraveineuse d’ACBP/DBI conservait son effet orexigène lorsque la protéine était mutée de façon à abolir la liaison à l’acyl-CoA, mais perdait cet effet chez les souris porteuses d’une mutation du récepteur GABA. Les anticorps anti-ACBP/DBI injectés par voie intraveineuse ou intrapéritonéale n’avaient pas d’action sur le comportement des souris. Cependant, l’injection d’ACBP/DBI augmentait l’immobilité au cours du test de nage forcée, tandis que l’injection d’un anticorps anti- ACBP/DBI annulait ce signe de dépression. Chez les patients souffrant de trouble bipolaire ou de schizophrénie, ACBP/DBI corrélait avec l’indice de masse corporelle quel que soit le diagnostic et n’était pas influencé par celui-ci. En résumé, il apparaît que la neutralisation d’ACBP/DBI n’entraine pas d’impact psychiatrique péjoratif et que son niveau chez l’homme n’est pas influencé par la présence d’un trouble bipolaire ou d’une schizophrénie. Nous nous sommes ensuite intéressés plus précisément aux rôles métaboliques d’ACBP/DBI. Nous avons montré que le knock-out d’ACBP/DBI dans le seul tissu adipeux était suffisant pour prévenir le développement de l’obésité induite par un régime riche en graisses. Sa neutralisation par un anticorps monoclonal spécifique réduisait la prise alimentaire excessive de souris en jeûne ou déficientes en leptine, mais pas chez les souris traitées par la ghréline. Nous avons ensuite mesuré les concentrations plasmatiques d’ACBP/DBI dans plusieurs cohortes de patients et retrouvé un double schéma de régulation. Chez des sujets sains, les concentrations d’ACBP/DBI corrélaient avec l’indice de masse corporelle et l’âge. Ces corrélations sont perdues chez les individus qui présenteront une importante prise de poids dans les années qui suivent le dosage, ainsi que chez les patients atteints d’un cancer avancé ou après un jeûne. Le jeûne volontaire, la dénutrition chez les patients atteints d’un cancer avancé et la chimiothérapie entrainaient une augmentation de la concentration plasmatique d’ACBP/DBI. En conclusion, ces résultats supportent l’hypothèse d’un rôle majeur d’ACBP/DBI dans la régulation du métabolisme énergétique ainsi que la perte de son homéostasie, et positionnent cette molécule comme une cible thérapeutique potentielle.

  • Open Access

    Acute kidney injury in immunocompromised patients with acute respiratory failure: insights from the HIGH clinical trial and relation with mechanical ventilation

    by Adrien Joseph, Michael Darmon, Laurent Argaud, Kada Klouche, François Barbier, Emmanuel Canet, Guillaume Louis, Alexandre Demoule, Christophe Girault, Samir Jaber, et al.

  • Presentation and Prognosis of Cryptococcosis Requiring Intensive Care Unit Admission in France: The CRYPTO-ICU Study

    by Simon Herbel, Olivier Paccoud, Étienne de Montmollin, Baptiste Grenier, Muriel Picard, Clara Vigneron, David Osman, Aëlle Le Gall, Juliette Guitard, Jérémie Joffre, et al.

    Background: Cryptococcus causes life-threatening opportunistic infections in immunocompromised hosts. Data on the most severe cases requiring intensive care unit (ICU) admission remain limited. Methods: We conducted a retrospective, multicenter study of patients admitted to 30 French ICUs for severe cryptococcosis between 2000 and 2022. Results: Among 151 patients included, 56.9% were patients with human immunodeficiency virus (HIV). Cases in patients without HIV became increasingly prevalent over time (51.3% in 2012–2022 vs 32.4% before 2012); 82.5% were receiving immunosuppressive therapy. Central nervous system infection was predominant (91.1%), followed by lung infection (39.7%). Fungemia occurred in 59.8% patients, and 75.2% had disseminated infection. Neurological failure was the leading organ impairment at admission (75.5%) followed by respiratory failure (47.7%), acute kidney injury (41.7%), and shock (24.5%). The median Sequential Organ Failure Assessment (SOFA) score was 4 (interquartile range, 2–7). Invasive mechanical ventilation, vasopressors, and renal replacement therapy were required in 54.9%, 34.4%, and 18.5% of patients, respectively. At day 90, 94% of patients requiring mechanical ventilation and vasopressors were deceased, compared to 38.7% with invasive ventilation alone and 17.2% without any organ support (P < .001). Overall, 90-day mortality reached 49.6%. SOFA score (adjusted hazard ratio [aHR], 1.04 [95% confidence interval [CI], 1.02–1.06]), admission between 2000 and 2012 (aHR, 2.30 [95% CI, 1.36–3.89]), disseminated infection (aHR, 2.32 [95% CI, 1.15–4.67]), and initiation of antifungal therapy before ICU admission (aHR, 0.38 [95% CI, .22–.63]) were independently associated with 90-day mortality, whereas HIV serostatus was not (aHR, 0.93 [95% CI, .47–1.84]). Conclusions: Severe cryptococcosis requiring ICU admission affects an increasing number of patients without HIV and is associated with high, though declining, mortality. Early diagnosis and treatment are mandatory to improve prognosis.

  • Urgences hypertensives en réanimation

    by Adrien Joseph, Victor Beaucoté, Sylvie Meireles

    Les urgences hypertensives regroupent un ensemble hétérogène de pathologies associées à une élévation brutale de la pression artérielle associée à l’atteinte d’un organe cible.Dans cette revue, nous décrivons la présentation initiale et les explorations indiquées devant une suspicion d’urgence hypertensive. En l’absence d’atteinte aigu d’un organe cible, une HTA sévère ne justifie pas la prescription d’un antihypertenseur parentérale mais requiert une adaptation ou une introduction d’un traitement antihypertenseur oral. Différents tableaux cliniques sont décrits dans cette revue : syndrome coronarien aigu, œdème pulmonaire, syndromes aortiques, encéphalopathie hypertensive et accidents vasculaires cérébraux, microangiopathie thrombotique et urgences hypertensives en contexte obstétrical sont successivement traités.La pharmacologie et les spécificités des antihypertenseurs parentéraux les plus fréquemment utilisés sont également abordés. Bien que les recommandations ne se basent pas sur des études de niveau de preuve élevées, le choix de la molécule anti-hypertensive et la vitesse de correction de l’hypertension artérielle doivent être adaptés à l’atteinte d’organe. La gestion des pics hypertensifs chez les patients de réanimation admis pour une autre cause, quant à elle, reste un domaine peu étudié.En conclusion, les urgences hypertensives regroupent différentes pathologies tant sur le plan physiopathologique que thérapeutique, dont les spécificités de prise en charge doivent être connues du réanimateur.

  • Diagnostic and Therapeutic Impact of Critical Care Echocardiography in Patients Admitted in the Intensive Care Unit for Circulatory Or Respiratory Failure Report from an Expert Center

    by Victor Penaud, Cyril Charron, Eve Garrigues, Pierre-Alexandre Haruel, Edouard Jullien, Romain Jouffroy, Sylvie Meireles, Matthieu Petit, Amélie Prigent, Victor Beaucote, et al.

    Purpose: Critical Care Echocardiography (CCE) is now a major tool in assessments of ICU patients. We aimed to evaluate its clinical impact in patients admitted to the intensive care unit for acute respiratory failure (ARF) or shock. Methods: We conducted a single-center retrospective observational study of all patients admitted between January 1th and December 31st 2019 for ARF or shock, who received CCE in the first 12 h of admission. The primary outcome was the therapeutic impact associated with CCE. Secondary outcomes included differences in therapeutic impact between ARF and shock patients, and between trans-thoracic (TTE) and trans-esophageal (TEE) CCE. Results: 486 patients were potentially eligible, 109 were excluded because CCE was performed after 12 h or because of missing CCE report. 329 patients were analyzed, 31% with shock, 44% with ARF, 25% with both. TTE was performed in 71%, TEE in 29%. All TEE patients were invasively mechanically ventilated and 65% of invasively ventilated patients underwent TEE. No TEE-related complications were observed. CCE was followed with 363 therapeutic interventions in 231 (70%) patients within 2 h. The most common involved hemodynamic optimization in 193 patients (59%), including fluid expansion (129 patients, 39%), vasopressor initiation (39 patients, 12%), vasopressor dose adjustment (79 patients, 24%), inotrope initiation (15 patients, 4.5%), inotrope dose adjustment (5 patients), and others like cardioversion (4 patients) and veno-arterial ECMO implantation (3 patients). TEE patients were more likely to receive therapeutic changes, notably significantly more fluids (53% vs 34% p = 0.0014) and had more frequent vasopressor dose adjustments (64% vs 24% p < 0.001). Conclusions: CCE was followed with therapeutic interventions in nearly 70% of patients admitted for ARF or shock, emphasizing its diagnostic value. Hemodynamic optimization was the primary intervention. We have not found any complications or adverse events of TEE in our cohort.

  • Open Access

    Previous treatment with anthracycline does not affect the course of sepsis in cancer patients: Retrospective cohort study

    by Camille Windsor, Adrien Joseph, Stephanie Pons, Djamel Mokart, Frederic Pène, Achille Kouatchet, Alexandre Demoule, Fabrice Bruneel, Martine Nyunga, Edith Borcoman, et al.


  • Fluid responsiveness in acute respiratory distress syndrome patients: a post hoc analysis of the HEMOPRED study

    by Adrien Joseph, Bruno Evrard, Matthieu Petit, Marine Goudelin, Gwenaël Prat, Michel Slama, Cyril Charron, Philippe Vignon, Antoine Vieillard-Baron

    Purpose Optimal fluid management in patients with acute respiratory distress syndrome (ARDS) is challenging due to risks associated with both circulatory failure and fluid overload. The performance of dynamic indices to predict fluid responsiveness (FR) in ARDS patients is uncertain. Methods This post hoc analysis of the HEMOPRED study compared the performance of dynamic indices in mechanically ventilated patients with shock, with and without ARDS, to predict FR, defined as an increase in aortic velocity time integral (VTI) > 10% after passive leg raising (PLR). Results Among 540 patients, 117 (22%) had ARDS and were ventilated with a median tidal volume of 7.6 mL/kg [6.9–8.4] and a median positive end-expiratory pressure of 7 cmH2O [5–9]. FR was observed in 45 ARDS patients (39% vs 44% in non-ARDS patients, p = 0.384). Reliability of dynamic indices to predict FR remained consistent in ARDS patients, though with different thresholds. Collapsibility index of the superior vena cava (ΔSVC) showed the best predictive performance in both ARDS (area under the curve [AUC] = 0.763 [0.659–0.868]) and non-ARDS (AUC = 0.750 [0.698–0.802]) patients. A right to left ventricle end-diastolic area ratio > 0.8 or paradoxical septal motion were strongly linked to the absence of FR (> 80% specificity). FR was not associated with intensive care unit (ICU) mortality (47% vs. 46%, p = 1). However, hypovolemia, defined as an aortic VTI increase > 32% during PLR (median increase in patients with a partial SVC collapse) was independently associated with ICU mortality (odds ratio [OR] = 1.355 [1.077—1.705], p = 0.011), as well as pulse pressure variation (OR = 1.014 [1.001—1.026], p = 0.034). Conclusion Performance of dynamic indices to predict FR appears preserved in ARDS patients, albeit with distinct thresholds. Hypovolemia, indicated by a > 32% increase in aortic VTI during PLR, rather than FR, was associated with ICU mortality in this population.